Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
IFN-alpha2a
DRUG
2 trials
Sponsors
National Center for Research Resources (NCRR)
, M.D. Anderson Cancer Center
Conditions
Alzheimer's Disease
Memory Disorders
Myeloproliferative Disorders
Phase 2
Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha
NCT00031018
National Center for Research Resources (NCRR)
Alzheimer's Disease, Memory Disorders
Updated: 2008-02-05
Pegasys® in Patients With Myeloproliferative Diseases
Completed
NCT00452023
M.D. Anderson Cancer Center
Myeloproliferative Disorders
Start: 2005-04-07
End: 2023-05-26
Updated: 2024-12-11
Related Papers
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
2017-11-09
31 citations
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
2017-03-11
90 citations